(MENAFN- B2Press) Lyon - BioNet, a biotechnology company focused on next-generation vaccines, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a marketing authorisation in the European Union for VacPertagen, a standalone acellular pertussis vaccine.

The benefits of VacPertagen were shown in 3 clinical studies in adults, adolescents, and pregnant women.

Expert perspectives on pertussis prevention

“Receiving a positive CHMP opinion for VacPertagen reflects years of scientific innovation and clinical development with collaborative efforts across continents,” said Prof. Emeritus Stanley Plotkin, chairman of the BioNet Scientific Advisory Board and an eminent expert in vaccinology.

“A pertussis-only vaccine is particularly valuable for use during pregnancy in countries where pertussis maternal immunisation programs are recommended for pregnant women who are up-to-date with their diphtheria and tetanus immunisations.”

BioNet leadership comments

“This is the first standalone pertussis vaccine to receive a CHMP favourable opinion through the centralised procedure in the European Union,” said Philippe Guillot-Chêne, CEO, BioNet Europe.

“This marks a historic milestone for BioNet and validates our vision to develop an improved pertussis-only vaccine specifically designed to address the re-emergence of pertussis globally.”

About pertussis disease

Pertussis is a highly contagious respiratory disease that poses a significant risk to newborns and older adults. The recent resurgence of pertussis cases across Europe underscores the urgent need to strengthen prevention through maternal immunisation and booster vaccination programs.

MENAFN24112025007075015205ID1110387285